Pfizer stock: New products lift 2026 outlook after Q3
Published on 11/06/2026 at 16:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer's Growth Mix Shifts
- Newly launched and acquired products grew 32 percent operationally in the third quarter.
- Pfizer raised its 2026 revenue and adjusted earnings outlook after stronger year-to-date performance.
- Pipeline milestones and research investment remain central to the company's return-to-growth strategy.
Pfizer raised its 2026 financial outlook after reporting third-quarter results on November 3, with newer products helping offset continued pressure on its COVID portfolio. The company said its launched and acquired products grew 32 percent operationally and contributed 3.8 billion US dollars to quarterly revenue.
According to Pfizer, third-quarter revenue reached 16.6 billion US dollars, while medicines for blood clots, cancer and migraine were important contributors. The company now expects 2026 revenue of 62.0 billion to 64.0 billion US dollars and adjusted diluted earnings per share of 2.95 to 3.05 US dollars.
New Products Carry More Weight
The updated outlook followed stronger year-to-date performance and continued financial discipline. Pfizer also reported 7.3 billion US dollars returned to shareholders through dividends during the first nine months of 2026.
Pipeline execution remains a central investment issue. Pfizer said that since its previous quarterly earnings update it had reached two regulatory decisions, one pivotal readout and eight pivotal study starts. Research and development spending reached 8.3 billion US dollars in the first nine months across oncology, vaccines, inflammation and immunology, and internal medicine.
Fresh Quote Sets Market Reference
Pfizer stock traded at 26.31 euros on Lang & Schwarz at 16:39 CET on Friday, November 6, 2026. Investors can follow the real-time quote of Pfizer stock as the market assesses whether newer products can sustain the improved outlook.
Pfizer Inc. at a glance
- Company: Pfizer Inc.
- ISIN: US7170811035
- Market: Lang & Schwarz
- Quote: 26.31 euros at 16:39 CET on November 6, 2026
- 2026 revenue outlook: 62.0 billion to 64.0 billion US dollars
- 2026 adjusted diluted EPS outlook: 2.95 to 3.05 US dollars
Broader sentiment for US-listed pharmaceutical companies can be followed in the S&P 500 market reports.
More news and analyses on Pfizer stock cover the company's outlook, pipeline milestones and product trends.
